Anthem Bioscienc

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0CZ201020
  • NSEID: ANTHEM
  • BSEID: 544449
INR
796.20
28.45 (3.71%)
BSENSE

Jun 18

BSE+NSE Vol: 13.44 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

782.20811.20

52 Week

620.05873.25
Valuation
Technical
Day's Volume

CASH

13.44 lacs (783.13%) Volume

Shareholding (Mar 2026)

FII

1.28%

Held by 37 FIIs

DII

11.55%

Held by 43 DIIs

Promoter

74.68%

Is Anthem Bioscienc overvalued or undervalued?

01-Sep-2025

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.<BR><BR>In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.

Read More

How has been the historical performance of Anthem Bioscienc?

09-Nov-2025

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

Answer:<BR>The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

Read More

Which are the latest news on Anthem Bioscienc?

03-Dec-2025
How has been the historical performance of Anthem Bioscienc?

Why is Anthem Bioscienc falling/rising?

04-Dec-2025

As of 03-Dec, Anthem Biosciences Ltd's stock price is at 662.75, reflecting a 1.6% increase. Despite a recent rise, concerns about declining investor participation and a 5.68% monthly drop indicate potential volatility ahead.

As of 03-Dec, Anthem Biosciences Ltd's stock price is rising, currently at 662.75, which reflects an increase of 10.45 or 1.6%. This upward movement is supported by the stock's performance today, where it outperformed its sector by 1.61%. Additionally, the stock reached an intraday high of Rs 667.15, marking a rise of 2.28%. <BR><BR>In the context of recent performance, the stock has shown a weekly increase of 4.79%, contrasting with a decline of 0.59% in the Sensex during the same period. However, it is important to note that the stock has experienced a decline of 5.68% over the past month, which indicates some volatility. <BR><BR>Despite this recent rise, there are concerns regarding falling investor participation, as evidenced by a significant drop in delivery volume, which decreased by 82.77% compared to the 5-day average. This could suggest a lack of sustained interest from investors, which may impact future price movements. Nevertheless, the current liquidity of the stock remains adequate for trading purposes.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
1

Low Debt Company with Strong Long Term Fundamental Strength

  • Healthy long term growth as Net Sales has grown by an annual rate of 29.80% and Operating profit at 44.32%
  • Company has a low Debt to Equity ratio (avg) at 0 times
  • The company has been able to generate a Return on Capital Employed (avg) of 31.00% signifying high profitability per unit of total capital (equity and debt)
2

The company declared positive results in Mar'26 after negative results in Dec'25

3

Increasing Participation by Institutional Investors

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 44,774 Cr (Large Cap)

stock-summary
P/E

71.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.34

stock-summary
Return on Equity

17.74%

stock-summary
Price to Book

13.59

Revenue and Profits:
Net Sales:
611 Cr
(Quarterly Results - Mar 2026)
Net Profit:
190 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.83%
0%
22.83%
6 Months
19.03%
0%
19.03%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Anthem Bioscienc for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News
Anthem Biosciences Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Market Returns

Anthem Biosciences Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Market Returns

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend. Despite a recent day decline of 0.87%, the stock’s technical indicators reveal a complex picture of emerging strength tempered by caution, as investors weigh the implications of mixed signals from key momentum and volume metrics.

Read More
Golden Cross Forms in Anthem Biosciences Ltd — Mixed Technical Signals Cloud the Outlook

Golden Cross Forms in Anthem Biosciences Ltd — Mixed Technical Signals Cloud the Outlook

The 50-day moving average has crossed above the 200-day moving average for Anthem Biosciences Ltd, signalling a golden cross on 20 May 2026. Yet, the stock declined 0.87% on the day the cross formed, while monthly technical indicators remain inconclusive. This divergence between the moving averages and other signals calls for a nuanced analysis of the cross's reliability.

Read More
Anthem Biosciences Downgraded to Sell Amid Technical Weakness and Financial Setbacks

Anthem Biosciences Downgraded to Sell Amid Technical Weakness and Financial Setbacks

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 18 May 2026. This shift reflects a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns, despite some positive long-term fundamentals and institutional interest.

Read More
Announcements stock-summary

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

05-Jun-2026 | Source : BSE

Schedule of Institutional Call to be held on June 10 2026

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

22-May-2026 | Source : BSE

Earnings Call transcript for Earnings Call held on May 20 2026 for the Audited Standalone and Consolidated financial results for the quarter and year ended March 31 2026.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

22-May-2026 | Source : BSE

Investors/Analyst Call Intimation to be schedule from June 02 2026 till June 05 2026.

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Anthem Biosciences Ltd has declared 100% dividend, ex-date: 25 Jun 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
29.80%
EBIT Growth (5y)
44.32%
EBIT to Interest (avg)
76.10
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.63
Tax Ratio
25.75%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.83%
ROCE (avg)
32.62%
ROE (avg)
19.93%
Valuation key factors
Factor
Value
P/E Ratio
71
Industry P/E
34
Price to Book Value
13.59
EV to EBIT
56.43
EV to EBITDA
49.83
EV to Capital Employed
18.42
EV to Sales
20.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
32.64%
ROE (Latest)
21.62%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bollinger Bands
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 27 Schemes (10.12%)

FIIs

Held by 37 FIIs (1.28%)

Promoter with highest holding

Ajay Bhardwaj (42.53%)

Highest Public shareholder

Portsmouth Technologies Llc . (2.74%)

Individual Investors Holdings

9.38%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 39.83% vs -24.56% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 88.79% vs -43.50% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "582.50",
          "val2": "416.58",
          "chgp": "39.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "266.99",
          "val2": "163.05",
          "chgp": "63.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.58",
          "val2": "1.13",
          "chgp": "39.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.97",
          "val2": "-24.98",
          "chgp": "103.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "211.67",
          "val2": "112.12",
          "chgp": "88.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "45.84%",
          "val2": "39.14%",
          "chgp": "6.70%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,090.24",
          "val2": "863.40",
          "chgp": "26.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "421.08",
          "val2": "324.04",
          "chgp": "29.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.84",
          "val2": "5.20",
          "chgp": "-26.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "346.77",
          "val2": "255.63",
          "chgp": "35.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.62%",
          "val2": "37.53%",
          "chgp": "1.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,506.82",
          "val2": "1,361.66",
          "chgp": "10.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "584.13",
          "val2": "490.89",
          "chgp": "18.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.97",
          "val2": "6.99",
          "chgp": "-28.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.98",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "458.89",
          "val2": "383.62",
          "chgp": "19.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.77%",
          "val2": "36.05%",
          "chgp": "2.72%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 15.17% vs 29.96% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 31.14% vs 22.86% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,124.33",
          "val2": "1,844.55",
          "chgp": "15.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "833.81",
          "val2": "670.83",
          "chgp": "24.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.89",
          "val2": "10.33",
          "chgp": "-33.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.39",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "591.79",
          "val2": "451.26",
          "chgp": "31.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "39.25%",
          "val2": "36.37%",
          "chgp": "2.88%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQstock-summary
Mar'26
Dec'25
Change(%)
Net Sales
582.50
416.58
39.83%
Operating Profit (PBDIT) excl Other Income
266.99
163.05
63.75%
Interest
1.58
1.13
39.82%
Exceptional Items
0.97
-24.98
103.88%
Standalone Net Profit
211.67
112.12
88.79%
Operating Profit Margin (Excl OI)
45.84%
39.14%
6.70%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 39.83% vs -24.56% in Dec 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 88.79% vs -43.50% in Dec 2025

All Quarterly Resultsstock-summary
Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary
Sep'25
Sep'24
Change(%)
Net Sales
1,090.24
863.40
26.27%
Operating Profit (PBDIT) excl Other Income
421.08
324.04
29.95%
Interest
3.84
5.20
-26.15%
Exceptional Items
0.00
0.00
Standalone Net Profit
346.77
255.63
35.65%
Operating Profit Margin (Excl OI)
38.62%
37.53%
1.09%
Values in Rs Cr.
stock-summary Compare with Peers
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Resultsstock-summary
Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary
Dec'25
Dec'24
Change(%)
Net Sales
1,506.82
1,361.66
10.66%
Operating Profit (PBDIT) excl Other Income
584.13
490.89
18.99%
Interest
4.97
6.99
-28.90%
Exceptional Items
-24.98
0.00
Standalone Net Profit
458.89
383.62
19.62%
Operating Profit Margin (Excl OI)
38.77%
36.05%
2.72%
Values in Rs Cr.
stock-summary Compare with Peers
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'26stock-summary
Mar'26
Mar'25
Change(%)
Net Sales
2,124.33
1,844.55
15.17%
Operating Profit (PBDIT) excl Other Income
833.81
670.83
24.30%
Interest
6.89
10.33
-33.30%
Exceptional Items
-24.39
0.00
Consolidate Net Profit
591.79
451.26
31.14%
Operating Profit Margin (Excl OI)
39.25%
36.37%
2.88%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 15.17% vs 29.96% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 31.14% vs 22.86% in Mar 2025

All Annual Resultsstock-summary
stock-summaryCompany CV
About Anthem Biosciences Ltd stock-summary
stock-summary
Anthem Biosciences Ltd
Large Cap
Pharmaceuticals & Biotechnology
Anthem Biosciences Limited was originally incorporated as "Anthem Biosciences Private Limited", dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to "Anthem Biosciences Limited" and a Certificate of Incorporation upon the conversion was issued by RoC on December 10, 2024.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support.ra@mojomarkets.in, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."